



Shionogi Joins the World Economic Forum and Signs the Davos Compact on Antimicrobial Resistance

- Contributing to the resolution of global healthcare challenges, including AMR, through international collaboration-

OSAKA, Japan, April 28, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; hereinafter, "Shionogi") today announced that it joined the World Economic Forum (WEF) on April 1, 2026, and signed the Davos Compact on Antimicrobial Resistance (AMR) on April 28, 2026.

The World Economic Forum, established in 1971 and headquartered in Switzerland, is an independent international organization committed to improving the state of the world. It engages leaders from business, government, academia, and civil society to shape global, regional, and industry agendas. The Forum provides platforms for dialogue on critical global issues, including through its Annual Meeting in Davos and various public-private partnership initiatives across sectors.

By joining the World Economic Forum, Shionogi will participate in the Health and Healthcare Centre, one of the Forum's collaborative platforms. Through engagement and dialogue with global public- and private-sector leaders, Shionogi will communicate its perspectives and positions, while appropriately incorporating global healthcare trends and policy developments gained through these interactions into the Group's business strategy and operations.

In conjunction with joining the Forum, Shionogi has also signed the Davos Compact on AMR (the "Compact").¹ The Compact was developed by the World Economic Forum's Global Future Council² on AMR in response to the Political Declaration on AMR³ adopted at the United Nations General Assembly High-Level Meeting in 2024. It aims to save more than 100 million lives by significantly reducing deaths attributable to AMR by 2050.

Through its participation in the Forum and its commitment to the Compact, Shionogi will further strengthen its efforts to address AMR, working in collaboration with stakeholders in Japan and globally to contribute to sustainable and effective solutions.

Shionogi has identified "Protecting people from the threat of infectious diseases" as one of its key material issues, and is advancing initiatives to deliver comprehensive care for infectious diseases. The Company will continue to play a responsible role across the entire value chain—including research and development, manufacturing, supply, and appropriate use—in addressing the global challenge of antimicrobial resistance. For more information on Shionogi's AMR initiatives, please visit the Company's website. [Address the problem of antimicrobial resistance \(AMR\)](#)

About Antimicrobial Resistance (AMR)

AMR refers to the phenomenon whereby bacteria become resistant to antimicrobial agents, rendering treatments less effective or ineffective, primarily due to the inappropriate use of antibiotics. Often described as

a “silent pandemic,” AMR is recognized as one of the most significant global public health threats, requiring urgent action.⁴ In 2021, AMR was estimated to have caused 1.14 million deaths worldwide.⁵ Without coordinated global action, it is projected to result in more than 39 million deaths over the next 25 years.⁶ Despite this growing threat, available treatment options remain limited, making AMR an area with significant unmet medical needs.

About the Health and Healthcare Centre

The World Economic Forum has established multiple platforms to address key global challenges, including the Health and Healthcare Centre. This platform brings together leading healthcare organizations from around the world to address critical issues, such as antimicrobial resistance (AMR), health security, climate change and health, and digital health, through collaborative initiatives.

References

1. [Davos Compact on AMR](#)
2. [Political Declaration of the High-level Meeting on Antimicrobial Resistance](#)
3. [Global Future Council on AMR](#)
4. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* 2022; 399: 629–55.
5. GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. *Lancet*. 2024 Sep 28;404(10459):1199-1226. doi: 10.1016/S0140-6736(24)01867-1. Epub 2024 Sep 16. PMID: 39299261.
6. [Antimicrobial resistance \(who.int\) WHO. Antimicrobial resistance. Who.int. Published October 13, 2020.](#)

For Further Information, Contact:

SHIONOGI Website Inquiry Form: <https://www.shionogi.com/global/en/contact.html>

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.